Table 5.
Frequency of cytogenetic aberrations in AML patients from the AML96DSIL study group carrying the GFI136S or GFI136N allele with regard to all aberrations in this group
| Type of aberration | GFI136S, % (n) | GFI136N, % (n) | P |
|---|---|---|---|
| t(8;21) | 17 (21) | 8 (1) | .62 |
| t(6;9) | 3 (4) | 0 | 1 |
| t(9;11) | 1 (1) | 0 | 1 |
| t(9;22) | 2 (2) | 0 | 1 |
| del(5q) | 10 (12) | 16 (2) | .3 |
| −del(7q) | 8 (9) | 17 (2) | .26 |
| inv(3q) | 1 (1) | 0 | 1 |
| inv(16) | 14 (17) | 16 (2) | .83 |
| −5 | 2 (2) | 8 (1) | .25 |
| −7 | 12 (14) | 16 (2) | .64 |
| −Y | 6 (7) | 8 (1) | .9 |
| −Trisomy 8 | 20 (23) | 25 (3) | .62 |
| Trisomy 11 | 3 (4) | 0 | 1 |
| −Trisomy 13 | 4 (5) | 0 | 1 |
| −Trisomy 21 | 5 (6) | 0 | 1 |
| Trisomy 22 | 4 (5) | 17 (1) | .44 |
| Complex | 32 (38) | 33 (4) | .74 |
| Abn(11q) | 8 (9) | 0 | 1 |
| Abn(12p) | 9 (10) | 8 (1) | 1 |
No significant difference for a specific aberration in association with the 2 GFI1 variants could be observed.
AML indicates acute myeloid leukemia; and GFI1, Growth Factor Independence 1.